BridgeBio Pharma (BBIO) Stock
Key stats
- Market cap
- $14.81B
- Price / Earnings ratio
- -25.7x
- EPS (TTM)
- -$3.03
- Volume
- Loading
- 52-week high
- $93.42
- 52-week low
- $62.50
- EPS vs analyst estimate
- -15.9%Q3 FY25 · -$0.95 vs -$0.82
Source: third-party data provider, as of November 22, 2026
EPS estimate: analyst consensus
Compare with BBIO
Recent news

Should You Invest $1,000 in BridgeBio Pharma Right Now?
Should You Invest $1,000 in BridgeBio Pharma Right Now?
BBIO

What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
BBIO

BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BBIO

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BBIO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.90
- MACD 12/26/9
- 2.10
- EMA 9 of MACD
- 2.21
- MACD histogram
- -0.11
- SMA 50
- $70.30
- Price above SMA 50
- EMA 50
- $73.37
- Price above EMA 50
- SMA 200
- $72.76
- Price above SMA 200
- EMA 200
- $72.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 20, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
Source: third-party data provider
Latest news

Should You Invest $1,000 in BridgeBio Pharma Right Now?
Should You Invest $1,000 in BridgeBio Pharma Right Now?
BBIO

What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
BBIO

BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BBIO

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BBIO

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BBIO

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BBIO

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BBIO

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BBIO

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
BBIO

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
BBIO
News tone: automated (AI) classification of the article's content, not a price prediction.
About BridgeBio Pharma
BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs includes product candidates ranging from early discovery to late-stage development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Neil Kumar Ph.D. | Co-Founder, CEO & Director | 1979 |
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy | 1972 |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Lead Director | 1948 |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology & Director | 1950 |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research & Development | 1953 |
| Dr. Thomas Trimarchi Ph.D. | CFO & President | 1985 |
| Ms. Maricel M. Apuli | Chief Accounting Officer | 1977 |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer | 1958 |
| Mr. Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology | 1967 |
| Mr. Matthew Outten CPC, MBA | Chief Commercial Officer | 1974 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 22, 2026
Technical indicators
- RSI 14
- 54.90
- MACD 12/26/9
- 2.10
- EMA 9 of MACD
- 2.21
- MACD histogram
- -0.11
- SMA 50
- $70.30
- Price above SMA 50
- EMA 50
- $73.37
- Price above EMA 50
- SMA 200
- $72.76
- Price above SMA 200
- EMA 200
- $72.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 20, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $91.00
- Average
- $109.78
- High
- $156.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.1 | -57.8 | ||||||||||
| 2022 | -42.5 | -27.8 | +21.4 | -26.1 | -18.9 | +37.8 | -12.7 | +24.1 | -2.7 | +0.6 | -10.2 | -17.4 |
| 2023 | +29.4 | +16.9 | +46.9 | -12.4 | -4.3 | +22.9 | +101.8 | -12.7 | -13.8 | +2.5 | +7.7 | +30.5 |
| 2024 | -15.2 | +2.5 | -13.2 | -14.5 | +3.6 | -12.6 | +3.0 | +6.4 | -11.4 | -5.6 | +6.3 | +3.2 |
| 2025 | +21.3 | +12.5 | +4.7 | +16.2 | -10.8 | +21.8 | +10.5 | +9.3 | +3.9 | +17.1 | +16.2 | +6.6 |
| 2026 | -1.2 | -15.0 | +13.4 | -4.5 | -3.4 | +14.0 | +7.5 | -4.2 | -14.1 | +12.0 | +1.4 |



